A new neoantigen selection algorithm that predicts T cell receptor interaction, combined with virus-like particle delivery, generated anti-tumor immune responses and slowed melanoma growth in mice.
TCR interaction = better predictionBy predicting how neoantigens interact with T cell receptors — not just MHC binding — the NOAH algorithm selected peptides that generated stronger anti-tumor immune responses when delivered via virus-like particles.
What the researchers found
Researchers developed a two-part innovation for cancer vaccines: a new computational algorithm (NOAH) that selects neoantigen peptides based on how they interact with both MHC molecules and T cell receptors (not just MHC binding alone), and an engineered virus-like particle (VLP) platform based on HIV-1 Gag that displays high copy numbers of these selected neoantigens. In a mouse melanoma model, VLPs loaded with neoantigens selected for enhanced TCR interaction generated new anti-tumor immune responses and delayed tumor growth. The study demonstrates that incorporating TCR interaction into neoantigen selection improves the immunogenicity of peptide cancer vaccines.
Why it matters
Current neoantigen prediction tools have poor accuracy because they mostly predict whether a peptide will bind MHC molecules — a necessary but insufficient condition for triggering an immune response. By also predicting how the peptide-MHC complex interacts with T cell receptors, the NOAH algorithm addresses a key bottleneck in personalized cancer vaccine development. Combined with an efficient VLP delivery platform that mimics viral structure to stimulate strong immune responses, this represents an improved pipeline from neoantigen identification to vaccine delivery.
The numbers in context
NOAH algorithm incorporating MHC-I binding + TCR interaction · HIV-1 Gag-based VLPs · High copy neoantigen display · B16-F10 melanoma model · Delayed tumor growth
How the study worked
The researchers developed the Neoantigen Optimization Algorithm (NOAH) incorporating structural prediction of peptide/MHC-I and peptide/MHC-I/TCR interactions. Neoantigens selected by NOAH were displayed on engineered HIV-1 Gag-based virus-like particles (neoVLPs) at high copy numbers. These neoVLPs were tested in B16-F10 melanoma mice for immunogenicity (generating new tumor-specific immune responses) and therapeutic efficacy (tumor growth delay in challenge experiments).
Who was studied
B16-F10 melanoma mouse model for in vivo immunogenicity and tumor challenge experiments
What this study cannot tell us
This is a preclinical mouse study using the B16-F10 melanoma model — one of the most commonly used but also most challenging mouse tumor models. The NOAH algorithm's accuracy improvement over existing methods is not quantified in the abstract. Human tumors have far more complex mutational landscapes and immune microenvironments. The HIV-1 Gag-based VLP platform, while effective in mice, may face manufacturing, regulatory, and perception challenges in clinical development. The study shows tumor growth delay but not complete rejection.
How to read the evidence
This is a preclinical study demonstrating proof-of-concept in one mouse tumor model. While the algorithmic innovation and VLP platform are well-characterized, the biological validation is limited to B16-F10 melanoma. No human data or comparison to clinical neoantigen vaccine approaches is provided.
When this study was published
Published in 2024, this is a recent contribution to the rapidly evolving field of neoantigen cancer vaccines. The computational and delivery innovations are at the cutting edge but remain preclinical.
The bigger picture
The field of personalized cancer vaccines is rapidly maturing, with several approaches in clinical trials. The two key bottlenecks remain neoantigen selection (choosing the right peptides) and delivery (presenting them to the immune system effectively). This study tackles both simultaneously. The NOAH algorithm addresses the well-known problem that most in-silico predicted neoantigens fail to generate immune responses, while the VLP platform provides an alternative to lipid nanoparticles and adjuvant-based approaches. As the field converges on optimal selection and delivery strategies, personalized cancer vaccines may finally achieve their long-promised clinical impact.
Questions still open
- How much does NOAH improve neoantigen prediction accuracy compared to existing MHC-binding-only algorithms?
- Can the VLP platform be manufactured at clinical scale for individual patients with unique neoantigen combinations?
- Would combining neoVLPs with checkpoint immunotherapy produce synergistic anti-tumor effects, as seen with other vaccine platforms?
Common questions
What are virus-like particles?
Why is predicting the 'right' neoantigen so hard?
Read the original research
Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Journal of translational medicine, 22(1), 14
Citation
Barajas, Ana; Amengual-Rigo, Pep; Pons-Grífols, Anna; Ortiz, Raquel; Gracia Carmona, Oriol; Urrea, Victor; de la Iglesia, Nuria; Blanco-Heredia, Juan; Anjos-Souza, Carla; Varela, Ismael; Trinité, Benjamin; Tarrés-Freixas, Ferran; Rovirosa, Carla; Lepore, Rosalba; Vázquez, Miguel; de Mattos-Arruda, Leticia; Valencia, Alfonso; Clotet, Bonaventura; Aguilar-Gurrieri, Carmen; Guallar, Victor; Carrillo, Jorge; Blanco, Julià. (2024). Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.. Journal of translational medicine, 22(1), 14. https://doi.org/10.1186/s12967-023-04843-8